Ocular Therapeutix (OCUL) Non-Current Debt (2013 - 2026)

Ocular Therapeutix's Non-Current Debt history runs 14 years deep, the most recent figure standing at $72.1 million for Q1 2026.

• On a quarterly basis, Non-Current Debt rose 4.13% year-over-year to $72.1 million in Q1 2026; TTM through Mar 2026 was $72.1 million, a 4.13% increase from a year earlier, with the FY2025 full-year figure at $71.3 million, up 4.13% from the prior year.
• Non-Current Debt improved to $72.1 million in Q1 2026 per OCUL's latest filing, from $71.3 million in the prior quarter.
• Across five years, Non-Current Debt topped out at $72.1 million in Q1 2026 and bottomed at $23.3 million in Q2 2023.
• The 5-year median for Non-Current Debt is $66.5 million (2024), against an average of $53.1 million.
• Across the five-year window, Non-Current Debt fell 7.26% in 2023 and surged 188.08% in 2024, its largest moves.
• Year by year, Non-Current Debt stood at $25.3 million in 2022, then surged by 160.47% to $65.8 million in 2023, then gained by 4.13% to $68.5 million in 2024, then rose by 4.13% to $71.3 million in 2025, then grew by 1.02% to $72.1 million in 2026.
• Per Business Quant, the three latest OCUL Non-Current Debt figures stand at $72.1 million (Q1 2026), $71.3 million (Q4 2025), and $70.6 million (Q3 2025).